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A Corrigendum on
Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO
Clinical Trial
by Berger M, Nelson B, Markulev C, Yuen HP, Schafer MR, Mossaheb N et al. (2019). Front.
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In the original article, Todd W. Mitchell and Barbara J. Meyer were not included as authors. The
corrected Author Contributions Statement appears below.
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In addition, there was a mistake in Table 2 as published. The
names of the following fatty acids are incorrect: 18:1n-7, 20:3n-6
and 22:5n-3/6. They should be 18:1, 20:3 and 22:5, respectively.
The corrected Table 2 appears below and the relevant changes to
the text have also been made.
The Methods section, subsection Fatty Acid Analysis:
“Total fatty acid levels were quantified from
erythrocyte samples col lected at base l ine .
Erythrocytes were separated from plasma and
extracted using an automated extraction method
described previously by (26). Fatty acid levels were
measured using mass spectrometry utilizing a hybrid
triple quadrupole linear ion trap mass spectrometer
(QTRAP 5500 AB Sciex, MA, USA) with an
automated chip-based nanoelectrospray source
(Triversa NanoMate, Advion Biosciences, New York,
USA). Ionized lipids identified with a minimum
signal-to-noise ratio of 10 were included in the
analysis. Identification and quantification was
accomplished using LipidView (v1.2, Sciex, MA,
USA). Quantification was performed using
LipidView software by comparing the spectral peak
area of individual lipids to their class specific internal
standards following isotope correction. Mass
spectrometry is unable to identify fatty acid double
bond isomers which limited our ability to distinguish
between 18:1n-7/9, 20:3n-3/6/9 and 22:5n-3/
6, respectively.”
A correction has been made to Results section, paragraphs 2
and 3:
“Partial correlations between fatty acids and related
indices and psychological variables, adjusted for age,
gender and smoking, are reported in Table 2. BPRS
scores were positively correlated with 24:0 (p < 0.001),
24:1n-9 (p < 0.001) and the n-6/3 PUFA ratio (p=0.01),
and negatively correlated with the n-3 index (p=0.003),
20:3 (p=0.010), 22:6n-3 (p < 0.001), 20:4n-6 (p=0.037)
and 18:2n-6 (p < 0.001). The BPRS psychotic symptoms
sub-scale was positively correlated with 24:1n-9
(p=0.009) and with the n-6/3 PUFA ratio (p=0.01),
and negatively correlated with 18:2n-6 (p=0.04) and
the n-3 index (p=0.008). Negative symptoms (SANS)
were positively correlated with 24:0 (p < 0.001) and
24:1n-9 (p < 0.001) and negatively correlated with 16:0
(p < 0.001), 20:3 (p < 0.001), 18:2n-6 (p < 0.001) and
18:1 (p=0.004).”
“YMRS scores were positively correlated with 24:0 (p <
0.0001) and 24:1n-9 (p < 0.0001) and negatively
correlated with 20:3 (p=0.002),20:5n-3 (p=0.03),
22:6n-3 (p < 0.0001), 18:2n-6 (p < 0.0011), 20:4n-6
(p < 0.0001) and the n-3-index (p < 0.0001). MADRS
scores were positively correlated with 24:0 (p <
0.0001), 24:1n-9 (p < 0.0001) and the n-6/3 PUFA
ratio (p=0.005), and negatively correlated with the n-
3-index (p=0.002), 20:3 (p=0.001), 22:6n-3 (p=0.001),
18:2n-6 (p < 0.0001), 20:4n-6 (p=0.03) and 18:1
(p=0.03). SOFAS scores were negatively correlated
with 18:0 (p=0.031). GF-S scores were positively
correlated with 18:2n-6 (p < 0.01) and 20:3 (p=0.01).
Finally, GF-R scores were positively correlated with
17:0 (p=0.02), 18:1 (p=0.04), 22:4n-6 (p=0.03) and
20:3 (p=0.01).”
TABLE 2 | Partial correlations of fatty acids with symptom and functioning scores in 285 participants of the Neurapro-E study.
BPRS BPRS psy SANS MADRS YMRS SOFAS GF-S GF-R
adj. R p-value adj. R p-value adj. R p-value adj. R p-value adj. R p-value adj. R p-value adj. R p-value adj. R p-value
16:0 -0.111 0.06 -0.011 0.86 -0.210 <0.001 -0.082 0.16 0.009 0.86 0.104 0.08 0.105 0.08 0.072 0.23
17:0 -0.015 0.79 0.029 0.63 -0.084 0.16 -0.011 0.85 -0.006 0.91 0.034 0.57 0.085 0.16 0.136 0.02
18:0 -0.029 0.62 -0.019 0.76 0.053 0.37 0.039 0.50 -0.055 0.35 -0.129 0.03 -0.113 0.06 -0.112 0.06
18:1* -0.119 0.04 -0.008 0.90 -0.191 0.001 -0.123 0.03 -0.140 0.02 0.109 0.06 0.065 0.28 0.121 0.04
18:2n-6 -0.344 <0.0001 -0.119 0.04 -0.328 <0.0001 -0.264 <0.0001 -0.324 <0.0001 0.033 0.57 0.146 0.01 0.047 0.44
20:3# -0.175 0.003 -0.105 0.08 -0.202 <0.001 -0.192 0.001 -0.184 0.002 0.102 0.08 0.153 0.01 0.150 0.01
20:4n-6 -0.162 0.006 -0.075 0.21 0.016 0.78 -0.122 0.03 -0.280 <0.0001 -0.016 0.78 0.016 0.79 -0.044 0.47
20:5n-3 0.005 0.92 -0.069 0.25 0.099 0.09 -0.039 0.50 -0.128 0.03 0.048 0.42 0.027 0.65 0.022 0.72
22:4n-6 -0.017 0.77 -0.065 0.28 0.109 0.07 -0.053 0.36 -0.080 0.18 -0.047 0.43 -0.071 0.24 -0.129 0.03
22:5^ 0.015 0.80 0.040 0.50 0.113 0.06 0.082 0.16 0.144 0.02 -0.002 0.97 -0.067 0.27 -0.116 0.05
22:6n-3 -0.198 <0.001 -0.166 0.006 -0.081 0.17 -0.191 0.001 -0.234 <0.0001 0.026 0.65 -0.007 0.90 -0.053 0.38
24:0 0.389 <0.001 0.099 0.09 0.289 <0.0001 0.307 <0.0001 0.375 <0.0001 -0.074 0.21 -0.098 0.10 -0.005 0.93
24:1n-9 0.365 <0.001 0.157 0.009 0.293 <0.0001 0.307 <0.0001 0.377 <0.0001 -0.074 0.21 -0.115 0.05 -0.047 0.44
n-3 index† -0.176 0.003 -0.160 0.008 -0.057 0.34 -0.177 0.002 -0.230 <0.0001 0.031 0.59 -0.002 0.97 -0.044 0.47
n-6/3 ratio& 0.153 0.01 0.147 0.01 0.093 0.12 0.169 0.005 0.118 0.05 -0.083 0.16 -0.021 0.73 0.035 0.56
* 18:1 could be 18:1n-7 or 18:1n-9, or a combination of both.
# 20:3 could be 20:3n-3, 20:3n-6 or 20:3n-9, or a combination of all 3 isomers.
^ 22:5 could be 22:5n-3 or 22:5n-6, or a combination of both.
†The n-3 index is calculated as the amount of EPA and DHA expressed as the percent of total fatty acids.
&The n-6/3 ratio is calculated as AA/(EPA + DHA).
Bold numbers indicate statistical significance.
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A correction has also been made to the Discussion section,
paragraph 1:
“The aim of this study was to investigate associations
of cel l membrane fatty acids with cl inical
characteristics in a large multi-centre RCT of fish oil
supplementation in individuals at UHR for psychosis.
After taking into account the effects of age, gender and
smoking, we found several PUFAs related to
psychopathology, including general psychopathology
(BPRS), psychotic symptoms (BPRS), negative
symptoms (SANS), manic symptoms (YMRS) and
depressive symptoms (MADRS). The n-3 index,
DHA, AA, 20:3, and 18:2n6 were negatively
correlated with BPRS, MADRS and YMRS scores,
while the n-6/3 PUFA ratio was positively correlated
with general psychopathology (BPRS), psychotic
symptoms (BPRS) and depressive symptoms
(MADRS). 24:0 and 24:1n-9 in turn were
significantly positively correlated with BPRS, SANS,
MADRS and YMRS scores. Collectively, these findings
support the notion that several classes of fatty acids are
associated with symptom severity in this group.”
Finally, the n-3 index was incorrectly described as the
proportion of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) relative to the total amount of n-3 fatty acids. It
should be “The n-3 index was calculated as the proportion of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
expressed as percent of total fatty acids.”
A correction has been made to Methods, subsection
Statistical Analysis:
“The n-3 index has been calculated as the proportion
of eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA) relative to the total amount of n-3 fatty
acids” has been changed to “The n-3 index was
calculated as the proportion of eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) expressed as
percent of total fatty acids.”
A correction has been made to the Discussion section,
paragraph 2:
“Our analysis contributes important insights into the
relationship between PUFA and psychopathology by
replicating findings of our previous smaller study in
UHR (23) in a large (n=285) and well-characterised
sample. Overall, our results confirm that higher levels
of n-3 PUFA (n-3 index) correspond to fewer
symptoms in this population. The n-3 index,
calculated as the sum of EPA and DHA as percent
of total fatty acids, was significantly associated with
lower general psychopathology (BPRS) scores, which
is broadly consistent with a previous study (27), as well
as with lower manic (YMRS) and depressive
(MADRS) symptoms. The n-6/n-3 PUFA ratio,
reflective of the balance between n-3 and n-6 PUFA,
was positively correlated with psychotic symptoms
(BPRS) and MADRS scores, suggesting that a higher
relative proportion of n-6 PUFA compared to n-3
PUFA correlates with more severe symptoms.
Consistent with the present findings, Kim et al. (23)
found that the n-6/n-3 PUFA ratio was associated with
psychotic symptoms, and the sum of n-3 PUFA
negatively with negative symptoms. This suggests
that the n-3 index is relevant to a range of
symptoms in the UHR state. Consistent with this,
DHA was also associated with lower BPRS scores in
our study. DHA is the most abundant n-3 PUFA in the
human brain and integral to the neuronal membrane.
Importantly, erythrocyte DHA correlates with grey
matter DHA (28) and may be particularly relevant
during adolescence, where increases in the level of
DHA may be critical for the development of the
prefrontal cortex and cortical maturation more
generally (29–31). Given that the UHR state and the
onset of psychotic disorders fall within this
developmental period in many cases, n-3 PUFA
including DHA may play a particularly important
role in this phase.”
The authors apologize for these errors and state that they do
not change the scientific conclusions of the article in any way.
The original article has been updated.
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